Loading
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Latest quote
$6.04
−$0.03 · -0.49%
After-hours
$5.9425
−$0.0975 · -1.61%
Sep 11, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Day range
Current $6.04
52-week range
Current $6.04
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
37
Expensive
Sentiment
65
Bullish
Risk
56
Elevated Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Day range
Current $6.04
52-week range
Current $6.04
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 6, 2020 | 1:4 | — | — |
Stock split | Apr 12, 2019 | 1:12 | — | — |
Stock split | May 5, 2017 | 1:10 | — | — |
Stock split | May 23, 2005 | 1:100 | — | — |
Effective Nov 6, 2020
1:4
Effective Apr 12, 2019
1:12
Effective May 5, 2017
1:10
Effective May 23, 2005
1:100
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.31M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM7.86M0.01%77.55B USD0.19%$288.89+0.41%
iShares Russell 2000 Growth ETFIWO2.88M0.02%14.32B USD0.24%$367.63+0.54%
Vanguard Extended Market ETFVXF2.42M0.00%93.7B USD0.05%$237.76+0.68%
Vanguard Russell 2000 ETFVTWO1.11M0.01%17.4B USD0.06%$116.76+0.36%
iShares Micro-Cap ETFIWC1.05M0.07%1.44B USD0.60%$190.84+0.39%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC542.17K0.05%1.06B USD0.20%$88.48+0.69%
Fidelity Enhanced Small Cap ETFFESM499.01K0.01%6.49B USD0.28%$46.36+0.78%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
